Radium-223 With Concomitant Therapy May Improve Overall Survival in mCRPC

Share this content:
Adding radium-223 to abiraterone or enzalutamide is safe and may prolong overall survival for patients with prostate cancer.
Adding radium-223 to abiraterone or enzalutamide is safe and may prolong overall survival for patients with prostate cancer.

Adding radium-223 to abiraterone or enzalutamide is safe and may prolong overall survival for patients with metastatic castration-resistant prostate cancer (mCRPC), a study published in The Lancet Oncology has shown.1

For this international, open-label, single-arm, phase 3b study, researchers enrolled 839 patients with progressive bone-predominant mCRPC and with 2 or more skeletal metastases on imaging.

Of enrolled patients, 696 received 1 or more doses of radium-223 and 403 completed all 6 planned injections. Use of other concomitant therapies, such as abiraterone, enzalutamide, and denosumab, were permitted.

Median overall survival was longer in patients who received radium-223 plus abiraterone, enzalutamide, or both, compared with those who did not receive abiraterone or enzalutamide (median, not reached versus 13 months).

Patients who received radium-223 with denosumab had a longer overall survival than those who received radium-223 with denosumab (median, not reached versus 13 months).

RELATED: Robotic Surgery for Prostate Cancer May Not Improve Quality of Life

Median overall survival was longer for men with: a baseline alkaline phosphatase concentration less than the upper limit of normal, a baseline hemoglobin level of 10 g/dL or greater, a baseline ECOG performance status of 0, and no reported baseline pain.

A total of 35% of patients reported any grade of serious adverse events. Treatment-emergent adverse events of any grade occurred for 75% of patients.                                

Reference

  1. Saad F, Carles J, Gillessen S, et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol. 2016 Jul 26. doi: 10.1016/S1470-2045(16)30173-5 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters